|
Jul 28
|
Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT
|
|
Jul 22
|
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
|
|
Jul 16
|
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
|
|
Jul 16
|
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
|
|
Jul 15
|
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
|
|
Jul 11
|
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside
|
|
Jul 10
|
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
|
|
Jul 10
|
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma
|
|
Jul 1
|
BioMarin Announces Completion of Acquisition of Inozyme
|
|
Jun 28
|
BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
|
|
Jun 27
|
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
|
|
Jun 26
|
The Top 5 Analyst Questions From BioMarin Pharmaceutical’s Q1 Earnings Call
|
|
Jun 24
|
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
|
|
Jun 23
|
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
|
|
Jun 23
|
2 Reasons to Watch BMRN and 1 to Stay Cautious
|
|
Jun 20
|
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
|
|
Jun 20
|
Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?
|
|
Jun 19
|
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About
|
|
May 28
|
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?
|
|
May 27
|
2 Value Stocks with Exciting Potential and 1 to Steer Clear Of
|